Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason S Lewis

Showing results (311-320 of 359) with videos related to

Pageof 36
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 25, 2024
First-in-Human Evaluation of Site-Specifically Labeled <sup>89</sup>Zr-Pertuzumab in Patients with HER2-Positive Breast CancerRandy Yeh, Joseph A O'Donoghue, Vetri Sudar Jayaprakasam, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 25, 2018
PARP-1-Targeted Radiotherapy in Mouse Models of GlioblastomaStephen A Jannetti, Giuseppe Carlucci, Brandon Carney, et al.
The Lancet. Oncology|May 31, 2024
Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranosticsAndrew M Scott, Brian M Zeglis, Suzanne E Lapi, et al.
Cancer Research|September 17, 2005
Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancerRenate Parry, Doug Schneider, Debra Hudson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 21, 2024
<sup>18</sup>F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal CancerSamuel L Cytryn, Neeta Pandit-Taskar, Melissa A Lumish, et al.
Medrxiv : the Preprint Server for Health Sciences|January 23, 2024
First-in-human imaging with [<sup>89</sup>Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostateSalomon Tendler, Mark P Dunphy, Matthew Agee, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 13, 2016
First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion UptakeNeeta Pandit-Taskar, Joseph A O'Donoghue, Shutian Ruan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 9, 2020
The Future of Nuclear Medicine, Molecular Imaging, and TheranosticsWolfgang A Weber, Johannes Czernin, Carolyn J Anderson, et al.
The Lancet. Oncology|July 1, 2024
Imaging with [<sup>89</sup>Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trialSalomon Tendler, Mark P Dunphy, Matthew Agee, et al.
Nature Communications|April 26, 2018
Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancerMichael R McDevitt, Daniel L J Thorek, Takeshi Hashimoto, et al.
Pageof 36

Showing results (311-320 of 359) with videos related to

Sort By:
Pageof 36
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 25, 2024
First-in-Human Evaluation of Site-Specifically Labeled <sup>89</sup>Zr-Pertuzumab in Patients with HER2-Positive Breast CancerRandy Yeh, Joseph A O'Donoghue, Vetri Sudar Jayaprakasam, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 25, 2018
PARP-1-Targeted Radiotherapy in Mouse Models of GlioblastomaStephen A Jannetti, Giuseppe Carlucci, Brandon Carney, et al.
The Lancet. Oncology|May 31, 2024
Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranosticsAndrew M Scott, Brian M Zeglis, Suzanne E Lapi, et al.
Cancer Research|September 17, 2005
Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancerRenate Parry, Doug Schneider, Debra Hudson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 21, 2024
<sup>18</sup>F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal CancerSamuel L Cytryn, Neeta Pandit-Taskar, Melissa A Lumish, et al.
Medrxiv : the Preprint Server for Health Sciences|January 23, 2024
First-in-human imaging with [<sup>89</sup>Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostateSalomon Tendler, Mark P Dunphy, Matthew Agee, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 13, 2016
First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion UptakeNeeta Pandit-Taskar, Joseph A O'Donoghue, Shutian Ruan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 9, 2020
The Future of Nuclear Medicine, Molecular Imaging, and TheranosticsWolfgang A Weber, Johannes Czernin, Carolyn J Anderson, et al.
The Lancet. Oncology|July 1, 2024
Imaging with [<sup>89</sup>Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trialSalomon Tendler, Mark P Dunphy, Matthew Agee, et al.
Nature Communications|April 26, 2018
Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancerMichael R McDevitt, Daniel L J Thorek, Takeshi Hashimoto, et al.
Pageof 36